It is expected that from the beginning of next week, you will start receiving COVID-19 related pathology messages directly into Mail Manager
Latest News
RESOLVED Service Outage Update – Vision Anywhere, Vision Online Service and Patient Services
Tags: Helpline
RESOLVED 16:00 - The outage with Vision Anywhere, Community Services, Vision Online Services and Patient Services due to a fault with an external hosting provider has now been resolved. Vision apologise for any impact this caused customers, practices and patients.
Coronavirus/Covid-19 SPL Patient Letter Update – England only 8th June 2020
Tags: England,Coronavirus
NHS Digital have provided us with an updated Shielded Patient List (SPL) letter for you to use when informing your patients they have been added to the SPL
NWIS have provided us with list of patients that newly qualify for the ‘at risk’ category. Overnight tomorrow tonight, these patients will have a Medical History entry added to their record to reflect this
We are pleased to announce that the new version of Vision Anywhere is now available on Windows Desktop, iOS and Android.
Please be aware the Coronavirus (Covid-19) Clinical Audit has been updated, the latest version is Version 9, dated 03/06/2020
Coronavirus/Covid-19 ‘At Risk’ Patients Utility – England only 3rd June 2020
Tags: England,Coronavirus
NHS England have provided us with a list of patients that newly qualify for the ‘at risk’ category, overnight tonight, these patients will have a Medical History entry added to their record to reflect this
NHS England have provided a list of Shielded Patient List (SPL) Subtractions. These are patients that for various reasons are no longer considered ‘high risk’ and now need updating to either ‘moderate’ or ‘low’ risk.
We have been made aware of a temporary product name change as a result of a supplier (Scope Ophthalmics Ltd) rebranding “VitA-POS eye ointment” to “Hylo Night eye ointment” for a short period of time during 2020, before reverting the name to “VitA-POS eye ointment”. There are no changes to the product formulation. The change of product name may affect your practice prior to the deployment of the June 2020 Gemscript release
There is a dedicated Yellow Card site for the reporting of new and emerging side effects and medical device incidents in COVID-19 treatments, this includes the reporting of side effects for medicines taken by patients to manage long-term or pre-existing conditions. Please report any new and emerging side effects and medical device incidents in COVID-19 treatments here